Tranexamic Acid Use for Bleeding Prevention in the Surgical Treatment of Metastatic Spinal Tumor in Lung Cancer Patients
Tranexamic Acid Use for Bleeding Prevention in the Surgical Treatment of Metastatic Spinal Tumor in Lung Cancer Patients: a Triple Blinded, Randomized Controlled Trial to Assess the Efficacy of Tranexamic Acid for Hemostasis
Second Affiliated Hospital, School of Medicine, Zhejiang University
150 participants
Dec 1, 2023
INTERVENTIONAL
Conditions
Summary
Massive blood loss occurs in metastatic spinal tumor resection and may cause severe complications. The objective of this study is to investigate whether the use of tranexamic acid will reduce perioperative and postoperative bleeding when compared to those without use of tranexamic acid.
Eligibility
Inclusion Criteria3
- Diagnosed as metastatic carcinoma of the thoracolumbar spine
- solitary neoplasm involve only one segment of spine
- patients underwent separation surgery
Exclusion Criteria4
- coagulation function was abnormal preoperatively
- patients are allergic to tranexamic acid
- neoplasm involve more than one segment of spine
- patients with rich blood supply who need embolization
Interventions
IV drip of 2 bottles of tranexamic acid (2g) before making incision during surgery； 1g tranexamic acid soaked gauze applied to the wound for 5 minintes before suture； patients were administered IV drip of tranexamic acid 3 times (every 8 hours)within 24 hours after surgery.
IV drip of 2 bottles of saline before making incision during surgery； saline soaked gauze applied to the wound for 5 minintes before suture； patients were administered IV drip of saline 3 times (every 8 hours)within 24 hours after surgery.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06023212